Rejoyn is a digital therapeutic application designed for adults aged 22 and older who are currently on antidepressant medication. It is FDA-authorized and classified as a medical device, offering brain-training exercises and skills-based therapy lessons over a six-week program. The app aims to enhance the effects of antidepressant medications by leveraging neuroplasticity, the brain's ability to change and adapt. Users can expect to engage with the program for less than two hours a week to potentially see improvements in their depression symptoms without any side effects related to the app.

Developed by a team of professionals in psychology, psychiatry, and neuroscience, Rejoyn was rigorously studied in a phase 3 clinical trial, demonstrating its efficacy as an adjunct treatment for Major Depressive Disorder (MDD). The app requires a prescription from a healthcare provider, ensuring that it complements existing medication regimens. It is important to note that Rejoyn is not a standalone treatment but rather a supplemental tool to be used under professional guidance.